Docoh
Loading...

ARQT Arcutis Biotherapeutics

GRANT
Utility
Topical roflumilast formulation having improved delivery and plasma half life
28 Sep 21
The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast.
David W. Osborne, Bhaskar Chaudhuri, Archie W. Thurston, Jr.
Filed: 31 Jan 20
APP
Utility
Method for Reducing Side Effects from Administration of PHOSPHODIESTERASE-4 Inhibitors
9 Sep 21
A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax.
Howard WELGUS, Archie W. THURSTON, JR., David W. Osborne
Filed: 21 May 21
APP
Utility
Inhibition of Crystal Growth of Roflumilast
12 Aug 21
Roflumilast crystals have been shown to increase in size during storage.
David W. Osborne
Filed: 23 Nov 20
APP
Utility
Roflumilast Formulations with an Improved Pharmacokinetic Profile
3 Jun 21
An improved a method of treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast.
Howard WELGUS, Archie THURSTON, David W. OSBORNE
Filed: 5 Feb 21
GRANT
Utility
Inhibition of crystal growth of roflumilast
9 Mar 21
Roflumilast crystals have been shown to increase in size during storage.
David W. Osborne
Filed: 20 Sep 18
APP
Utility
Topical Roflumilast Formulation Having Improved Delivery and Plasma Half Life
27 May 20
The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast.
David W. OSBORNE, Bhaskar CLAUDHURI, Archie W. THURSTON, Jr.
Filed: 30 Jan 20
APP
Utility
Method for Reducing Side Effects from Administration of PHOSPHODIESTERASE-4 Inhibitors
20 May 20
A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax.
Howard WELGUS, Archie W. THURSTON, JR., David W. Osborne
Filed: 5 Sep 19
APP
Utility
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time
4 Dec 19
Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition.
David W. OSBORNE
Filed: 29 May 19
  • 1
Patents are sorted by USPTO publication date, most recent first